Salesforce
CRM
Coinbase
COIN
Oracle
ORCL
4
Tesla
TSLA
5
Microsoft
MSFT
US Stock MarketDetailed Quotes
CTXR Citius Pharmaceuticals
- 0.8739
- +0.0319+3.79%
Close Apr 24 16:00 ET
- 0.8932
- +0.0193+2.21%
Post 20:01 ET
8.18MMarket Cap-0.15P/E (TTM)
0.9000High0.8224Low152.89KVolume0.8500Open0.8420Pre Close131.43KTurnover1.78%Turnover RatioLossP/E (Static)9.36MShares26.250052wk High0.13P/B7.52MFloat Cap0.800152wk Low--Dividend TTM8.61MShs Float750.0000Historical High--Div YieldTTM9.22%Amplitude0.8001Historical Low0.8590Avg Price1Lot Size
Citius Pharmaceuticals Key Stats
Quarterly+Annual
YOY
| (Q1)Dec 31, 2024 | (FY)Sep 30, 2024 | (Q4)Sep 30, 2024 | (Q3)Jun 30, 2024 | (Q2)Mar 31, 2024 | (Q1)Dec 31, 2023 | (FY)Sep 30, 2023 | (Q4)Sep 30, 2023 | (Q3)Jun 30, 2023 | (Q2)Mar 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating revenue | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 |
| Cost of revenue | ||||||||||
| Gross profit | ||||||||||
| Operating expense | 7.48%10.04M | 14.33%42M | 9.14%11.05M | 22.63%10.63M | 2.67%10.97M | 28.84%9.34M | 10.25%36.73M | 34.11%10.12M | -2.74%8.67M | 40.77%10.69M |
| Selling and administrative expenses | 17.77%7.91M | 37.32%30.09M | 12.34%8.14M | 60.38%7.87M | 23.59%7.36M | 76.61%6.72M | 39.92%21.91M | 96.14%7.24M | 21.82%4.91M | 43.98%5.96M |
| -General and administrative expense | 17.77%7.91M | 37.32%30.09M | 12.34%8.14M | 60.38%7.87M | 23.59%7.36M | 76.61%6.72M | 39.92%21.91M | 96.14%7.24M | 21.82%4.91M | 43.98%5.96M |
| Research and development costs | -18.87%2.13M | -19.66%11.91M | 1.12%2.91M | -26.58%2.76M | -23.71%3.61M | -23.90%2.62M | -16.06%14.82M | -25.27%2.88M | -22.98%3.76M | 36.92%4.73M |
| Operating profit | -7.48%-10.04M | -14.33%-42M | -9.14%-11.05M | -22.63%-10.63M | -2.67%-10.97M | -28.84%-9.34M | -10.25%-36.73M | -34.11%-10.12M | 2.74%-8.67M | -40.77%-10.69M |
| Net non-operating interest income expense | -91.09%22.61K | -35.73%758K | -63.88%117.31K | -39.18%204.84K | -39.92%182.21K | 18.22%253.64K | 369.14%1.18M | 140.91%324.81K | 535.19%336.78K | 925.58%303.28K |
| Non-operating interest income | -91.09%22.61K | -35.73%758K | -63.88%117.31K | -39.18%204.84K | -39.92%182.21K | 18.22%253.64K | 369.14%1.18M | 140.91%324.81K | 535.19%336.78K | 925.58%303.28K |
| Other net income (expense) | -33.41%2.39M | 0 | 2.39M | 3.59M | 0 | |||||
| Other non- operating income (expenses) | ---- | -33.41%2.39M | --0 | ---- | --2.39M | ---- | --3.59M | --0 | ---- | ---- |
| Income before tax | -10.23%-10.02M | -21.53%-38.85M | -11.56%-10.93M | -25.12%-10.43M | 19.09%-8.4M | -163.42%-9.09M | 3.32%-31.97M | -32.17%-9.8M | 5.96%-8.34M | -37.31%-10.38M |
| Income tax | 83.50%264.24K | 0.00%576K | 0.00%144K | 0.00%144K | 0.00%144K | 0.00%144K | 0.00%576K | -75.00%144K | 144K | 144K |
| Net income | -11.38%-10.28M | -21.15%-39.43M | -11.40%-11.08M | -24.70%-10.57M | 18.83%-8.54M | -156.88%-9.23M | 3.26%-32.54M | -24.44%-9.94M | 4.34%-8.48M | -39.21%-10.53M |
| Net income continuous Operations | -11.38%-10.28M | -21.15%-39.43M | -11.40%-11.08M | -24.70%-10.57M | 18.83%-8.54M | -156.88%-9.23M | 3.26%-32.54M | -24.44%-9.94M | 4.34%-8.48M | -39.21%-10.53M |
| Minority interest income | -513K | -287K | 0 | 0 | ||||||
| Net income attributable to the parent company | -5.82%-9.77M | -20.27%-39.14M | -8.51%-10.79M | -24.70%-10.57M | 18.83%-8.54M | -156.88%-9.23M | 3.26%-32.54M | -24.44%-9.94M | 4.34%-8.48M | -39.21%-10.53M |
| Preferred stock dividends | ||||||||||
| Other preferred stock dividends | -9.02%1.05M | -36.96%725.75K | 321.56K | 1.15M | 1.15M | 0 | ||||
| Net income attributable to common stockholders | -5.82%-9.77M | -19.27%-40.19M | -3.79%-11.52M | -28.49%-10.89M | 18.83%-8.54M | -156.88%-9.23M | -0.16%-33.69M | -38.85%-11.1M | 4.34%-8.48M | -39.21%-10.53M |
| Basic earnings per share | 10.34%-1.3 | -7.18%-5.97 | 5.49%-1.72 | 0.00%-1.5 | 28.57%-1.25 | -190.00%-1.45 | 3.13%-5.57 | -45.60%-1.82 | 0.00%-1.5 | -40.00%-1.75 |
| Diluted earnings per share | 10.34%-1.3 | -7.18%-5.97 | 5.49%-1.72 | 0.00%-1.5 | 28.57%-1.25 | -190.00%-1.45 | 3.13%-5.57 | -45.60%-1.82 | 0.00%-1.5 | -40.00%-1.75 |
| Dividend per share | ||||||||||
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- |
Market Insights
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Unlock Now
Discussing
Trade war escalates: What’s next for Chinese stocks?
🎙️Discussion 1. China-EU EV negotiations kick off recently. How do you think the negotiations will impact the performance of related stocks
Moo Earnings
Feb 17 19:21
Alibaba Q4 FY2024 Earnings Preview: Predict & Win Big! 🚀